Kornimate/medical-research-clean huggingface dataset:
measuring change in overcoming implicit biases in behavior by emergency care center providers

Conditions: Implicit Bias

Summary: implicit bias is a form of bias in which a person's automatic and unintentional thoughts of another person or group influence either positively or negatively their behavior or the decisions they make. studies show that healthcare providers have the same amount of bias as any other person and that it can affect patient care. however, in the emergency room, which is fast-paced and there is a high number of patients, implicit bias may be higher. therefore, this study will look at emergency care center (ecc) providers' willingness to change their implicit bias behaviors. after, it will provide implicit bias education designed for the ecc to the healthcare providers at smhcs sarasota campus and assess whether it improved their willingness to change implicit bias behaviors when compared to the providers in the smhcs venice campus who did not receive the education.

studies have shown that implicit bias is present in healthcare providers, including those in the emergency room, it is necessary to understand whether emergency providers are willing to change their implicit bias behaviors and provide them with the education and resources tailored to it so that they can be aware of it and make a positive change towards improving it even when they are pressured by time and never-ending tasks. the observational study will use a two-group pretest-posttest design to assess willingness to change implicit bias behaviors among healthcare staff in the ecc. healthcare providers will be recruited from two smhcs clinical sites: sarasota memorial hospital's (smh) -sarasota campus ecc and smh's-venice campus ecc. participants are expected to fill out the initial surveys, complete the implicit bias education, and do the posttest (re-administer the measuring change in overcoming implicit biases in behavior by emergency medicine personnel questionnaire), which is expected to take approximately 6-18 months.

Eligibility criteria:
inclusion criteria: * individuals will be eligible for the study if they are 18 years or older and are active emergency medicine staff in the smh-sarasota or the smh-venice campus ecc. participants must also be able to understand the requirements of the study, be willing and able to provide informed consent, and participate in all required study activities. exclusion criteria: * n/a

Keywords: healthcare providers implicit bias emergency care center
genetics of aortic stenosis: from family forms to the common forms

Conditions: Aortic Stenosis

Summary: the association study will compare the allele frequencies of polymorphisms of a single nucleotide (snp) in the population of individuals with aortic stenosis compared to a control population. patients will be included only if they are suffering from a typical form of tight and surgical tricuspid aortic stenosis. patients will therefore only included if they are suffering from aortic stenosis, the surface is less than 1 cm² and if histological analysis or failing intraoperative findings of the surgeon showed a tricuspid aortic stenosis.


Eligibility criteria:
inclusion criteria: 1. criteria has reached: * that patients are operated or not, they can be considered as having a degenerative aortic stenosis, patients will be diagnosed with aortic stenosis (aortic area \<1 cm) without obvious cause found. 2. criteria not met * strictly normal aortic valve by ultrasound in an over 65-year-old patient. * all patients do not fit into the above two categories are considered as having an unknown phenotype and will not be used in binding assays. in particular, the presence of an aortic sclerosis or even moderate aortic regurgitation can be considered as potentially incipient form of aortic stenosis, patients with this type of anomaly will not be scanned during family analyzes. exclusion criteria: * patients who did not sign the consent * non degenerative aortic stenosis or for which another cause could be found. among the most commonly found causes are: * bicuspid aortic valve * severe renal impairment * severe hypercholesterolemia
study to determine safety/efficacy of lucentis for treatment of retinal angiomatous proliferation secondary to age related macular degeneration

Conditions: Macular Degeneration

Summary: the primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

this study will be a phase i/ii open label interventional case series. twenty patients with retinal angiomatous proliferation will be randomized to receive intravitreal ranibizumab at a dose of 0.3mg/0.05 ml or 0.5mg/0.05 ml. patients will receive ranibizumab via a pars plana injection on a monthly basis for a total duration of therapy of 12 months. patients will be followed for a complete 12-month treatment course.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent and comply with study assessments for the full duration of the study. * age \> 50 years * definite characteristic signs of age related macular degeneration including drusen * presence of retinal angiomatous proliferation as determined by clinical signs (intra retinal hemorrhage, retinal edema, cystic retinal edema) and angiography (occult leakage on fluorescein angiography, hot spot on static icg, visible rap lesion of high speed icg) exclusion criteria: * prior treatment with verteporfin, external-beam radiation therapy, or transpupillary thermotherapy in the study eye (predominantly classic cnv can however only be included if the subject had up to 3 prior pdt treatments) * treatment with verteporfin in the non-study eye less than 7 days preceding day 0 * previous participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase c inhibitors, etc.) * previous subfoveal focal laser photocoagulation involving the foveal center in the study eye * laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding day 0 * history of vitrectomy, submacular surgery, or other surgical intervention for amd in the study eye * previous participation in any studies of investigational drugs within 1 month preceding day 0 (excluding vitamins and minerals)

Keywords: macular degeneration age related macular degeneration retinal angiomatous proliferations
anal fistula and microdialysis - what is yet to learn?

Conditions: Anal Fistula

Summary: anal fistula can be a challenging condition to treat. microdialysis has never before been used to examine the inner environment of anal fistula. this is now going to be performed.

patients with anal fistula can have a reduced quality of life for years do to fistula complications. this condition is not well researched and more knowledge is needed to provide better care. microdialysis has been used to study other organs of the body such as the brain, liver and gi-tract. upcoming study is going to study the inner environment of the anal fistula in regards to lactate, pyruvate and glucose. the study group is patients with anal fistula that with a need for seton treatment. measurements with microdialysis will take place before operative procedure and one month after getting their seton inserted.

Eligibility criteria:
inclusion criteria: * over 18 years of age * to be able to understand and accept the terms of study exclusion criteria: * age under 18 * dementia, language barrier
feasibility and preliminary effects of mr-005 in persons with parkinson disease

Conditions: Parkinson Disease

Summary: the purpose of this clinical study is to evaluate the effects of music, tailored to the participant's cadence, on adherence, quality of life, gait speed, functional mobility, and walking activity in individuals with parkinson disease when used in the home and community environment.

persons with parkinson disease will be enrolled to determine the effects of a community walking program with a music-based device on adherence, quality of life, walking speed and walking activity. the walking program will be carried out independently by participants in their home/community environment. noninvasive functional assessments commonly administered in clinical practice will be used to measure the variables of interest.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic, typical parkinson disease. * modified hoehn and yahr stages 1-3 per physical exam. * able to walk independently without physical assistance or an assistive device. exclusion criteria: * diagnosis of atypical parkinsonism. * moderately or significantly disturbing freezing episodes during daily walking. * cognitive impairment as determined by the montreal cognitive assessment (moca). * significant hearing impairment. * currently participating in physical therapy. * cardiac problems that interfere with the ability to safely exercise. * orthopedic problems in the lower extremities or spine that may limit walking distance.
magnitude of changes in 25 oh vitamin d3 levels after vitamin d3 supplementation

Conditions: Vitamin D Deficiency

Summary: vitamin d deficiency is common world wide. 25 oh vitamin d level is the best indicator of vitamin d status. the determination of the appropriate dose of vitamin d supplement is essential for management of vitamin d deficiency as well as for designing vitamin d fortification programs. the increments in 25 oh vitamin d levels following various doses of vitamin d supplement for different genders, body weights, and starting 25 oh vitamin d level have not been well defined. the time course of depletion of repleted vitamin d stores is also not known. the investigators plan to conduct a double blind randomized study on 9 cohorts to determine levels of 25 oh vitamin d following supplementation with different doses of vitamin d3 for 5 months and their withdrawal for 3 months.


Eligibility criteria:
inclusion criteria: * adults living in riyadh area who consume no more than one serving of milk/day, do not take vitamin supplement, habitually have less than 10 hr of sun exposure per week, don't suffer from granulomatous conditions, liver disease, or kidney disease, and don't take anticonvulsants, barbiturates, or steroids. * individuals with with total 25 oh vitamin d level exceeding 100 nmol/l will be excluded from the study. individuals with 25 oh vitamin d levels less than 20 nmol/l will be excluded from the placebo arm.

Keywords: vitamin d3, 25 oh vitamin d3 level
pharmacokinetics of bictegravir in adults with normal and impaired renal function

Conditions: HIV

Summary: the primary objective of this study is to evaluate the pharmacokinetic (pk) profile of oral bictegravir (formerly gs-9883) in adults with impaired renal function relative to matched, healthy controls with normal renal function. each participant in the renal impairment groups will be matched for age (± 10 years), gender, and body mass index \[bmi (± 20%, 18 ≤ bmi ≤ 40 kg/m\^2)\] with a participant in the control group.


Eligibility criteria:
key inclusion criteria: * all individuals: * must have a calculated bmi from 18 to 40 kg/m\^2, inclusive, at screening * individuals with impaired renal function * chronic stable renal impairment without recent clinical change * mild: creatinine clearance (crcl) = 60 - 89 ml/min * moderate: crcl = 30 - 59 ml/min * severe: crcl = 15 - 29 ml/min * healthy individuals * crcl ≥ 90 ml/min key exclusion criteria: * all individuals: * pregnant or lactating females * hiv positive or chronic hepatitis b infected * individuals with impaired renal function * chronic liver disease * dialysis or anticipated use of dialysis * renal transplant note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: phase 1 renally impaired
thermal and pulsed ultrasound for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Median Neuropathy, Carpal Tunnel

Summary: this study will be a randomized controlled trial with a sample size of at least 100 individuals with carpal tunnel syndrome. participants will be randomized to receive either thermal ultrasound, pulsed ultrasound, a combination of both, or a placebo treatment for 10 minutes, three times per week, for 4 weeks. outcome measures will include pain intensity, functional status, and nerve conduction studies. outcome measures will be assessed at baseline, 4 weeks, and 8 weeks.


Eligibility criteria:
inclusion criteria: 1. adults aged 30-60 years old 2. diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies, including: * symptoms of pain, numbness, and tingling in the hand and/or fingers, particularly the thumb, index, and middle fingers * positive tinel's sign (tapping over the median nerve at the wrist elicits tingling or numbness in the hand) * positive phalen's maneuver (flexion of the wrist for 60 seconds elicits tingling or numbness in the hand) * abnormal nerve conduction studies showing prolonged distal motor latency, and/or decreased amplitude of the median nerve exclusion criteria: 1. prior surgery for carpal tunnel syndrome 2. history of wrist or hand fracture in the past year 3. pregnancy or planning to become pregnant during the study period 4. active infection or skin condition in the treatment area 5. known allergy to ultrasound gel or other components of the treatment 6. use of corticosteroids or other medications that may affect nerve function within the past 3 months 7. participation in another clinical trial within the past 30 days
dietary fiber for fecal incontinence

Conditions: Fecal Incontinence

Summary: the primary aim of this study was to compare the effects of supplementation with one of three dietary fibers (gum arabic, carboxy-methylcellulose, or psyllium) or a placebo on fecal incontinence (fi), symptom intolerance, and quality of life in community-living individuals who have incontinence of loose or liquid feces. a secondary aim was to explore the possible mechanism(s) underlying the supplements' efficacy (i.e., improvements in stool consistency, water-holding capacity or gel formation).


Eligibility criteria:
inclusion criteria: * age ≥18 years * living in the community (not a nursing home or assisted living facility) * self-report of usually having fi of loose or liquid consistency at least twice in a 2-wk period * toilets independently * ability to read and write in english. * persons that regularly performed pelvic floor muscle exercises and/or biofeedback on a maintenance regimen for at least 20 wks or who took a steady dose of anti-motility medications on a regular schedule that still met the fi criteria were also eligible. exclusion criteria: * difficulty swallowing, * a gastrointestinal (gi) tract altered by surgery, * a malabsorption disorder, * inflammatory bowel disease, * gastrointestinal cancer or active cancer treatment, * allergy to the fibers, * regularly used a laxative or enema, were tube-fed, or unwilling to discontinue taking periodic self-prescribed fiber supplements or anti-diarrheal medications. * a score ≤24 on the mini mental state examination * having/reporting fewer than two episodes of fi or being incapable of performing study procedures during the run-in baseline period

Keywords: fecal incontinence, dietary fiber
a decision aid for patients with age-related cataract

Conditions: Age-related Cataract

Summary: to determine whether a decision aid increases informed decision about cataract surgery for patients with age-related cataract.

the need for cataract surgery is on the rise globally due to the aging population and high demands for greater visual functioning. patients with age-related cataract face their initial decision about when to undergo cataract surgery. although the majority of patients want to participate in a shared decision-making process, no decision aid has been available to improve the quality of decision. the purpose of this study is to determine whether a decision aid increases informed decision about cataract surgery for patients with age-related cataract.

Eligibility criteria:
inclusion criteria: 1. individuals aged 50-80 years who have been resident in the selected study district for more than six months; 2. a definite diagnosis of age-related cataract; 3. having not received cataract surgery; 4. willing to participate in the study and provide informed content. exclusion criteria 1. bilateral blindness (presenting distance visual acuity worse than 3/60); 2. having ocular, hearing or mental disorder precluding reading or telephone interview; 3. ocular disorders other than cataract leading to permanent vision loss that could not be corrected through cataract surgery; 4. having cataract surgery contraindication.
depression, anxiety and stress in high school

Conditions: Depression; Anxiety; Stress

Summary: background: social isolation secondary to the pandemic can predispose the population to mental health issues in the future, especially teenagers. the depression, anxiety, and stress scale (dass) is a valuable self-report scale since it may be used to screen for anxiety, depression, and stress in one questionnaire. in the last years, it has been observed effective in detecting these symptoms in teenagers. aims: identify the prevalence of depression, anxiety, and stress in high school students during the covid-19 pandemic this is an observational cross-sectional study. for this study, the validated spanish version of dass-21 will be used. qualitative variables will be evaluated through central tendencies, such as mean, standard deviation, and frequencies. the inferential analysis of categorical variables will be performed using the chi-squared test, analysis of variance (anova), or kruskal wallis test as appropriate. for quantitative variables, student's t-test or mann whitney u test will be performed depending on their distribution.


Eligibility criteria:
inclusion criteria: * adolescents from 14 to 22 years old. * that they voluntarily agree to participate, and consent. exclusion criteria: * adolescents with depression, anxiety, and stress disorders previously detected * patients in psychiatric treatment for depression, anxiety, or stress. * participants who don´t consent to participate
a study to evaluate the efficacy of diabetes management based on ubiquitous healthcare system

Conditions: Diabetes Mellitus

Summary: the aim of this study is to investigate whether adding tailored mobile coaching system to present community primary care for diabetes management would result in better glycemic control and other diabetes-related outcomes in adult patients with type 2 diabetes, compared with maintaining usual diabetes management only.

the incidence and prevalence of type 2 diabetes is increasing rapidly worldwide. considering the fact that complications of diabetes result in greater expenditure and reduced productivity is a socioeconomic concern, adequate glycemic control is important not only as individual health problem but also as challenge to healthcare systems worldwide. to support patients' behavior change efforts, including healthy lifestyle choices, disease self-management, and prevention of diabetes complication, multifaceted professional interventions are needed. ubiquitous healthcare based on information and communication technology is one of these approaches. the aim of this study is to investigate whether adding tailored mobile coaching system to present community primary care for diabetes management would result in better glycemic control and other diabetes-related outcomes in adult patients with type 2 diabetes, compared with maintaining usual diabetes management only.

Eligibility criteria:
inclusion criteria: * korean policyholders with type 2 diabetes; * aged ≥ 19 years; * smartphone users; * glycated hemoglobin (hba1c) ≥ 6.5% within 3 months. exclusion criteria: * currently had serious concomitant disease other than diabetes; * had admission histories due to malignancy, myocardial infarction, cerebral infarction, or organ transplantation; * pregnant or had plan for pregnancy within 6 months; * planned for attending other clinical; * illiteracy.
randomized, double-blind, safety and efficacy of recombinant human erythropoietin in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (als). the aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhepo) therapy in als patients.


Eligibility criteria:
inclusion criteria: * age between 25 to 80 * upper motor neuron signs and lower motor neuron signs were identified in neurological examination. * meet the revised el escorial criteria for clinically possible, probable-laboratory -supported, probable, definite als. * disease duration \< 3 years (within 3 years from symptom onset) * alsfrs-r score between 21 to 46 * patient who can visit an outpatient under the aid of his or her own walking or caregivers. * the person who have agreed in writing to participate in this clinical trial by themselves and the legal representative * fvc over 50% at screening exclusion criteria: * person who were not compatible with als * patient with pls or pma * a group of patients who are concerned about the adverse effects of the drug administration (e.g. malignant hypertension,...) * alsfrs-r score below 20 at screening * ventilator user or tracheostomy state patients at screening * gastrostomy state at screening * fvc below 50% at screening or patient who cannot perform fvc test. * ekg abnormality, history of coronary stent , cabg at screening * person who was given another clinical trial drug three months prior to screening. * history of seizure/ epilepsy * abnormal renal function (serem creatinine \> 2.0mg/dl) * abnormal liver function(ast/alt/bilirubin over 2 times the upper normal limit * pregnant * bleeding tendency at screening * infectious disease at screening * drug sensitivity * person who injected erythropoietin 6 months prior to screening * malignant tumor * other neurological disease (stroke, parkinson's disease, dementia...) * psychological disease * hb more than 16g/dl
efficacy study of nivolumab compared to docetaxel in subjects previously treated with advanced or metastatic non small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: the purpose of this study is to determine whether nivolumab improves life expectancy compared to docetaxel in subjects with advanced or metastatic non-small cell lung cancer who have failed prior platinum-based doublet chemotherapy.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * disease progression experienced during or after one prior platinum containing doublet chemotherapy * stage iiib/iv or recurrent disease * male and female ≥ 18 years of age * measurable disease per recist 1.1 * performance status ≤ 1 exclusion criteria: * history of carcinomatous meningitis * active central nervous system (cns) metastases * history of auto immune diseases * prior treatment with docetaxel * prior treatment with ipilimumab or any drug targeting t-cell costimulation or checkpoint pathways